NAME OF THE MEDICINAL PRODUCT

Dysport.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Per Vial

Active Constituent

Clostridium botulinum type A toxin-haemagglutinin complex    500U *

Other Constituents

Albumin solution    125 MCG

Lactose    2.5 MG

* One unit (U) is defined as the median lethal intraperitoneal dose in mice.

3    PHARMACEUTICAL FORM

Injection.

4    CLINICAL PARTICULARS

4.1    Therapeutic indications

Dysport is indicated for focal spasticity, including the treatment of:

-    arm symptoms associated with focal spasticity in conjunction with physiotherapy; and

-    dynamic equinus foot deformity due to spasticity in ambulant paediatric cerebral palsy patients, two years of age or older, only in hospital specialist centres with appropriately trained personnel.

Dysport is also indicated for the following treatments:

-    Spasmodic torticollis in adults

- Blepharospasm in adults

- Hemifacial spasm in adults.

4.2    Posology and method of administration

The units of Dysport are specific to the preparation and are not interchangeable with other preparations of botulinum toxin.

Training: Dysport should only be administered by appropriately trained physicians.

Ipsen can facilitate training in administration of Dysport injections.

The exposed central portion of the rubber stopper should be cleaned with alcohol immediately prior to piercing the septum. A sterile 23 or 25 gauge needle should be used.

Arm spasticity

Posology

Adults: The recommended dose is 1000 units in total, distributed amongst the following five muscles:

Biceps brachii (BB)	Flexor digitorum profundus (FDP)	Flexor digitorum superficialis (FDS)	Flexor carpi ulnaris (FCU)	Flexor carpi radialis FCR)	Total Dose
300-400 units (0.6-0.8 mL)	150 units (0.3 mL)	150-250 units (0.3-0.5 mL)	150 units (0.3 mL)	150 units (0.3 mL)	1000 units (2.0 mL)

The sites of injection should be guided by standard locations used for electromyography, although actual location of the injection site will be determined by palpation. All muscles except the biceps brachii (BB) should be injected at one site, whilst the biceps should be injected at two sites.

The dose should be lowered if there is evidence to suggest that this dose may result in excessive weakness of the target muscles, such as for patients whose target muscles are small, where the BB muscle is not to be injected or patients who are to be administered multi-level injections. Clinical improvement may be expected within two weeks after injection. Data on repeated and long term treatment are limited.

Children: The safety and effectiveness of Dysport in the treatment of arm spasticity in children have not been demonstrated.

Method of administration

When treating arm spasticity, Dysport is reconstituted with 1.0 mL of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per mL of botulinum toxin type A.

Dysport is administered by intramuscular injection into the five muscles detailed above when treating arm spasticity.

Paediatric cerebral palsy spasticity

Posology

The initial recommended dose is 20 units/kg body weight given as a divided dose between both calf muscles. If only one calf is affected, a dose of 10 units/kg bodyweight should be used. Consideration should be given to lowering this starting dose if there is evidence to suggest that this dose may result in excessive weakness of the target muscles, such as for patients whose target muscles are small or patients who require concomitant injections to other muscle groups. Following evaluation of response to the starting dose subsequent treatment may be titrated within the range 10 units/kg and 30 units/kg divided between both legs. The maximum dose administered must not exceed 1000 units/patient.

Administration should primarily be targeted to the gastrocnemius, although injections of the soleus and injection of the tibialis posterior should also be considered.

The use of electromyography (EMG) is not routine clinical practice but may assist in identifying the most active muscles.

Clinical improvement may be expected within two weeks after injection. Injections may be repeated approximately every 16 weeks or as required to maintain response, but not more frequently than every 12 weeks.

Method of administration

When treating paediatric cerebral palsy spasticity, Dysport is reconstituted with 1.0 mL of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per mL of botulinum toxin type A.

Dysport is administered by intramuscular injection into the calf muscles when treating spasticity.

Spasmodic torticollis

Posology

Adults and elderly: The doses recommended for torticollis are applicable to adults of all ages providing the adults are of normal weight with no evidence of low neck muscle mass.

A reduced dose may be appropriate if the patient is markedly underweight or in the elderly, where reduced muscle mass may exist.

The initial recommended dose for the treatment of spasmodic torticollis is 500 units per patient given as a divided dose and administered to the two or three most active neck muscles.

•    For rotational torticollis distribute the 500 units by administering 350 units into the splenius capitis muscle, ipsilateral to the direction of the chin/head rotation and 150 units into the sternomastoid muscle, contralateral to the rotation.

•    For laterocollis, distribute the 500 units by administering 350 units into the ipsilateral splenius capitis muscle and 150 units into the ipsilateral sternomastoid muscle. In cases associated with shoulder elevation the ipsilateral trapezoid or levator scapulae muscles may also require treatment, according to visible hypertrophy of the muscle or electromyographic (EMG) findings. Where injections of three muscles are required, distribute the 500 units as follows, 300 units splenius capitis, 100 units sternomastoid and 100 units to the third muscle.

•    For retrocollis distribute the 500 units by administering 250 units into each of the splenius capitis muscles. This may be followed by bilateral trapezius injections (up to 250 units per muscle) after 6 weeks, if there is insufficient response. Bilateral splenii injections may increase the risk of neck muscle weakness.

•    All other forms of torticollis are highly dependent on specialist knowledge and EMG to identify and treat the most active muscles. EMG should be used diagnostically for all complex forms of torticollis, for reassessment after unsuccessful injections in non complex cases, and for guiding injections into deep muscles or in overweight patients with poorly palpable neck muscles.

On subsequent administration, the doses may be adjusted according to the clinical response and side effects observed. Doses within the range of 250-1000 units are recommended, although the higher doses may be accompanied by an increase in side effects, particularly dysphagia. Doses above 1000 units are not recommended.

The relief of symptoms of torticollis may be expected within a week after the injection. Injections should be repeated approximately every 12 weeks or as required to prevent recurrence of symptoms.

Children: The safety and effectiveness of Dysport in the treatment of spasmodic torticollis in children have not been demonstrated.

Method of administration

When treating spasmodic torticollis Dysport is reconstituted with 1.0 mL of sodium chloride injection B.P. (0.9%) to yield a solution containing 500 units per mL of botulinum toxin type A.

Dysport is administered by intramuscular injection as above when treating spasmodic torticollis.

Blepharospasm and hemifacial spasm Posology

Adults and elderly: In the treatment of bilateral blepharospasm the recommended initial dose is 120 units per eye.

Injection of 0.1 mL (20 units) should be made medially and of 0.2.mL (40 units) should be made laterally into the junction between the preseptal and orbital parts of both the upper and lower orbicularis oculi muscles of each eye.

For injections into the upper lid the needle should be directed away from its centre to avoid the levator muscle. A diagram to aid placement of these injections is provided. The relief of symptoms may be expected to begin within two to four days with maximal effect within two weeks.

Injections should be repeated approximately every 12 weeks or as required to prevent recurrence of symptoms. On such subsequent administrations the dose may need to be reduced to 80 units per eye - viz -: 0.1 mL (20 units) medially and 0.1 mL (20 units) laterally above and below each eye in the manner previously described. The dose may be further reduced to 60 units per eye by omitting the medial lower lid injection.

In cases of unilateral blepharospasm the injections should be confined to the affected eye. Patients with hemifacial spasm should be treated as for unilateral blepharospasm. The doses recommended are applicable to adults of all ages including the elderly.

Children: The safety and effectiveness of Dysport in the treatment of blepharospasm and hemifacial spasm in children have not been demonstrated.

Method of administration

When treating blepharospasm and hemifacial spasm, Dysport is reconstituted with 2.5 mL of sodium chloride injection BP (0.9%) to yield a solution containing 200 units per mL of botulinum toxin type A.

Dysport is administered by subcutaneous injection medially and laterally into the junction between the preseptal and orbital parts of both the upper and lower orbicularis oculi muscles of the eyes.

4.3    Contraindications

Dysport is contraindicated in individuals with known hypersensitivity to any components of Dysport.

4.4    Special warnings and precautions for use

Dysport should only be used with caution and under close supervision in patients with subclinical or clinical evidence of marked defective neuro-muscular transmission (e.g. myasthenia gravis). Such patients may have an increased sensitivity to agents such as Dysport which may result in excessive muscle weakness with therapeutic doses. Patients with underlying neurological disorders are at increased risk of this side effect.

Patients with a history of dysphagia and aspiration should be treated with extreme caution. Swallowing or breathing disorders can worsen due to the spread of toxin distant from the site of administration. Aspiration has occurred in rare cases and is a risk when treating patients who have a chronic respiratory disorder. Dysport should be used under specialist supervision in all such patients and should only be used if the benefit of treatment is considered to outweigh the risk.

Side effects related to spread of toxin distant from the site of administration have been reported (see section 4.8), which in some cases was associated with dysphagia, pneumonia and /or significant debility resulting in death very rarely. Patients and their care-givers must be warned of the necessity of immediate medical treatment in case of problems with swallowing, speech or respiratory disorders.

Careful consideration should be given before the injection of patients who have experienced a previous allergic reaction to a product containing botulinum toxin type A. The risk of a further allergic reaction must be considered in relation to the benefit of treatment.

Antibody formation to botulinum toxin has been noted rarely in patients receiving Dysport. Clinically, neutralising antibodies have been detected by a substantial deterioration in response to therapy and /or a need for consistently increasing doses.

For the treatment of cerebral palsy in children, Dysport should only be used in children over 2 years of age.

The recommended posology and frequency of administration for Dysport must not be exceeded (see section 4.2).

Dysport should only be used to treat a single patient, during a single session. Specific precautions must be taken for the preparation and administration of the product (see section 4.2) and for the inactivation and disposal of any unused reconstituted solution (see section 6.6).

As with any intramuscular injection, Dysport should be used only where strictly necessary in patients with prolonged bleeding times, infection or inflammation at the proposed injection site.

This product contains a small amount of human albumin. The risk of transmission of viral infection cannot be excluded with absolute certainty following the use of human blood or blood products.

4.5 Interaction with other medicinal products and other forms of interaction

The effects of botulinum toxin may be enhanced by drugs interfering directly or indirectly with the neuromuscular function (e.g. aminoglycosides, curare-like non-depolarising blockers) and such drugs should be used with caution in patients treated with botulinum toxin.

4.6 Pregnancy and lactation

Teratological and other reproductive studies have not been performed with Dysport. The safety of its use in pregnant or lactating women has not been demonstrated.

Dysport should not be used in pregnant or lactating women, unless clearly necessary.

4.7    Effects on ability to drive and use machines

Dysport may impair the ability to drive or operate machinery in case of adverse reactions such as muscle weakness and eye disorders (diplopia, blurred vision, eyelid ptosis).

4.8    Undesirable effects

Very common >1/10: Common >1/100, <1/10: Uncommon >1/1000, <1/100:

Rare >1/10 000, < 1/1000: Very rare <1/10 000.

Side effects related to spread of toxin distant from the site of administration have been reported (exaggerated muscle weakness, dysphagia, aspiration/aspiration pneumonia, with fatal outcome in some very rare cases) (see section 4.4).

General

In the clinical trial programme, approximately 28% of the patients treated with Dysport experienced an adverse event.

The following adverse reactions were seen in patients treated across a variety of indications including blepharospasm, hemifacial spasm, torticollis and spasticity associated with either cerebral palsy or stroke:

Nervous system disorders

Rare: Neuralgic amyotrophy

Skin and subcutaneous tissue disorders Uncommon: Itching Rare: Skin rashes

General disorders and administration site conditions

Common: Generalised weakness, fatigue, flu-like syndrome, pain / bruising at injection site.

In addition, the following adverse reactions specific to individual indications were reported:

Arm spasticity

Gastrointestinal disorders

Common: Dysphagia

Musculoskeletal and connective tissue disorders Common: Arm muscle weakness

Injury, poisoning and procedural complications Common: Accidental injury/falls

Paediatric cerebral palsy spasticity

Gastrointestinal disorders

Common: Diarrhoea, vomiting

Musculoskeletal and connective tissue disorders Common: Leg muscle weakness

Renal and urinary disorders

Common: Urinary incontinence

General disorders and administration site conditions Common: Abnormal gait

Injury, poisoning and procedural complications Common: Accidental injury due to falling

Accidental injury due to falling and abnormal gait may have been due to the over-weakening of the target muscle and / or the local spread of Dysport to other muscles involved in ambulation and balance.

Spasmodic torticollis

Nervous system disorders

Common: Dysphonia Uncommon: Headache

Eye disorders

Uncommon: Diplopia, blurred vision

Respiratory, thoracic and mediastinal disorders Rare: Respiratory disorders

Gastrointestinal disorders

Very common: Dysphagia Uncommon: Dry mouth

Musculoskeletal and connective tissue disorders Common: Neck muscle weakness

Dysphagia appeared to be dose related and occurred most frequently following injection into the sternomastoid muscle. A soft diet may be required until symptoms resolve.

These side effects may be expected to resolve within two to four weeks.

Blepharospasm and hemifacial spasm

Nervous system disorders

Common: Facial muscle weakness Uncommon: Facial nerve paresis

Eye disorders

Very common: Ptosis

Common: Diplopia, dry eyes, tearing

Rare: Ophthalmoplegia

Skin and subcutaneous tissue disorders Common: Eyelid oedema Rare: Entropion

Side effects may occur due to deep or misplaced injections of Dysport temporarily paralysing other nearby muscle groups.

Post-marketing experience

The profile of adverse reactions reported to the company during post-marketing use reflects the pharmacology of the product and those seen during clinical trials. In addition, hypersensitivity reactions have been reported.

4.9 Overdose

Excessive doses may produce distant and profound neuromuscular paralysis. Respiratory support may be required where excessive doses cause paralysis of respiratory muscles. There is no specific antidote; antitoxin should not be expected to be beneficial and general supportive care is advised. Overdose could lead to an increased risk of the neurotoxin entering the bloodstream and may cause complications associated with the effects of oral botulinum poisoning (e.g deglutition and dysphonia).

Symptomatic treatment should be instituted if necessary. In the event of an overdose the patient should be medically monitored for several weeks for symptoms of systemic weakness or muscle paralysis.

5    PHARMACOLOGICAL PROPERTIES

5.1    Pharmacodynamic properties

Clostridium botulinum type A toxin-haemagglutinin complex blocks peripheral cholinergic transmission at the neuromuscular junction by a presynaptic action at a site proximal to the release of acetylcholine. The toxin acts within the nerve ending to antagonise those events that are triggered by Ca which culminate in transmitter release. It does not affect postganglionic cholinergic transmission or postganglionic sympathetic transmission.

The action of toxin involves an initial binding step whereby the toxin attaches rapidly and avidly to the presynaptic nerve membrane. Secondly, there is an internalisation step in which toxin crosses the presynaptic membrane, without causing onset of paralysis. Finally the toxin inhibits the release of acetylcholine by disrupting the Ca²+ mediated acetylcholine release mechanism, thereby diminishing the endplate potential and causing paralysis.

Recovery of impulse transmission occurs gradually as new nerve terminals sprout and contact is made with the post synaptic motor endplate, a process which takes 6 - 8 weeks in the experimental animal.

5.2    Pharmacokinetic properties

Pharmacokinetic studies with botulinum toxin pose problems in animals because of the high potency, the minute doses involved, the large molecular weight of the compound and the difficulty of labelling toxin to produce sufficiently high specific activity. Studies using I125 labelled toxin have shown that the receptor binding is specific and saturable, and the high density of toxin receptors is a contributory factor to the high potency. Dose and time responses in monkeys showed that at low doses there was a delay of 2 - 3 days with peak effect seen 5 - 6 days after injection. The duration of action, measured by changes of ocular alignment and muscle paralysis varied between 2 weeks and 8 months. This pattern is also seen in man, and is attributed to the process of binding, internalisation and changes at the neuromuscular junction.

5.3 Pre-clinical safety data

There is no further pre-clinical information relevant to the prescribing physician that has not been included in other sections of the Summary of Product Characteristics.

PHARMACEUTICAL PARTICULARS

6.1. List of excipients

Albumin and Lactose.

6.2 Incompatibilities

None known.

6.3    Shelf life

The shelf life of the packaged product is 24 months at 2-8°C.

The product may be stored for up to 8 hours at 2-8°C following reconstitution.

Since the product does not contain an antimicrobial agent, from a microbiological point of view, it is recommended that the product should be used immediately following reconstitution.

6.4 Special precautions for storage

Unopened vials must be maintained at temperatures between 2°C and 8°C. Dysport must be stored in a refrigerator at the hospital where the injections are to be carried out and should not be given to the patient to store.

Reconstituted Dysport may be stored in a refrigerator (2-8°C) for up to 8 hours prior to use. Dysport should not be frozen.

6.5    Nature and contents of container

Nature of container/closure:

Type 1 glass vials 3 mL capacity. 13 mm chlorbutyl freeze-drying closures oversealed by 13 mm aluminium overseals with centre hole, crimped over.

Contents of container:

A white lyophilised powder for reconstitution.

6.6    Special precautions for disposal

Immediately after treatment of the patient, any residual Dysport which may be present in either vial or syringe should be inactivated with dilute hypochlorite solution (1% available chlorine). Thereafter, all items should be disposed of in accordance with standard hospital practice.

Spillage of Dysport should be wiped up with an absorbent cloth soaked in dilute hypochlorite solution.

7. MARKETING AUTHORISATION HOLDER

Ipsen Limited 190 Bath Road Slough Berkshire SL1 3XE United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 06958/0005

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION

9th December 1990

10 DATE OF REVISION OF THE TEXT

28/04/2009